Today: 23 March 2026
Subscribe
Browse Category

Stock Market 9 January 2026

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Kohl’s shares fell 5.1% to $20.66 Friday afternoon, underperforming retail peers, after the Supreme Court delayed a decision on Trump-era tariffs. The broader market steadied following a softer jobs report, with nonfarm payrolls up 50,000 in December and unemployment at 4.4%. Investors remain uncertain about potential $150 billion in tariff refunds as the next court ruling is expected Jan. 14.
9 January 2026
·
Star Bulk Carriers (SBLK) stock drops nearly 5% as dry-bulk freight gauge slips

Star Bulk Carriers (SBLK) stock drops nearly 5% as dry-bulk freight gauge slips

Star Bulk Carriers shares dropped 4.8% to $19.76 by early afternoon Friday as the Baltic Dry Index slid to 1,688, down 31% in a month. The company last reported Q4 2025 TCE at $19,500 per day and paid a $0.11 dividend for Q3. Investors await the next results update on Feb. 25. Genco Shipping fell 3.7%, while Safe Bulkers and Diana Shipping edged higher.
9 January 2026
····
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines shares rose 4.3% to $112.00 Friday after reports that Merck is in talks to buy the company for up to $32 billion. The FDA granted Breakthrough Therapy designation to Revolution’s KRAS-targeting lung cancer drug this week. AbbVie denied involvement in any deal. Revolution declined to comment on the takeover speculation.
9 January 2026
··
Establishment Labs stock slides 5%: traders eye Motiva FDA next steps and JPM conference talk

Establishment Labs stock slides 5%: traders eye Motiva FDA next steps and JPM conference talk

Establishment Labs shares fell about 5% to $69.22 in early Friday trading, reversing part of a 10% gain earlier in the week. The drop came as broader U.S. markets rose on a softer December jobs report. Investors are watching for updates at the company’s Jan. 14 J.P. Morgan Healthcare Conference presentation and awaiting FDA review of its Motiva breast implants.
9 January 2026
·
Gold price stock rally: GLD, Newmont climb after soft U.S. jobs data lifts bullion

Gold price stock rally: GLD, Newmont climb after soft U.S. jobs data lifts bullion

Spot gold rose 0.6% to $4,502.98 an ounce Friday after U.S. payrolls data missed forecasts, pushing bullion near record highs. SPDR Gold Shares gained 0.3%, while Newmont, Agnico Eagle, and Franco-Nevada advanced. Investors await U.S. Supreme Court tariff rulings Jan. 14 and the Fed’s Jan. 27-28 meeting for further policy signals.
9 January 2026
······
Vistra stock jumps as Meta locks in 20-year nuclear power deal for AI data centers

Vistra stock jumps as Meta locks in 20-year nuclear power deal for AI data centers

Vistra shares rose 11% to $167.11 by midday Friday after Meta signed 20-year nuclear power purchase agreements for 2,609 MW, with deliveries starting in late 2026. The deals cover Vistra’s Perry, Davis-Besse, and Beaver Valley plants. Investors focused on capital spending for upgrades and license extensions. Meta aims to secure power for its Ohio data center and future AI operations.
9 January 2026
·····
Qfin Holdings (QFIN) stock slides as China fintech ADRs lag on tariff limbo, credit jitters

Qfin Holdings (QFIN) stock slides as China fintech ADRs lag on tariff limbo, credit jitters

Qfin Holdings shares dropped 4.5% to $17.32 in Friday afternoon trading, hitting a session low of $17.21. FinVolution and LexinFintech also declined, as investors weighed U.S. tariff uncertainty and concerns over rising Chinese consumer loan defaults. China’s regulator recently extended a program for banks to offload bad loans. The broader U.S. market traded higher.
9 January 2026
·····
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Soleno Therapeutics shares fell 5.6% to $42.95 Friday, underperforming the biotech sector after law firms announced “investigations” tied to past short-seller claims about Vykat XR. The company reported $66 million in quarterly revenue from the drug, approved for Prader-Willi syndrome, with 1,043 patient start forms since March. The stock hovered just above its 52-week low. Next update expected late February.
9 January 2026
··
Bitcoin price wobbles near $90,000 as ETF outflows bite; Coinbase, Strategy stocks slide

Bitcoin price wobbles near $90,000 as ETF outflows bite; Coinbase, Strategy stocks slide

Bitcoin slipped 0.5% to about $90,700 Friday, while Coinbase fell 2% and Strategy nearly 5% in U.S. trading. Ether and XRP also declined. Investors pulled nearly $885 million from U.S. spot bitcoin ETFs over two days this week. Traders are watching U.S. inflation data due Jan. 13 and the Fed’s Jan. 27-28 meeting.
9 January 2026
······
IREN stock rises as Bernstein calls it a “top AI pick” — what traders watch next

IREN stock rises as Bernstein calls it a “top AI pick” — what traders watch next

IREN shares rose 4.6% to $47.76 Friday, trading between $45.52 and $49.99 in heavy volume. Bernstein analyst Gautam Chhugani named IREN his top AI pick for 2026, according to TipRanks. Investors are watching for February earnings and signs of capital needs tied to the company’s AI expansion. IREN operates renewable-powered data centers in Canada and Texas and signed a $9.7 billion AI cloud deal with Microsoft last year.
9 January 2026
···
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now

Wave Life Sciences shares dropped 5.6% to $14.00 on Friday, underperforming biotech ETFs. The decline follows a $350 million stock offering and comes ahead of new obesity drug trial data expected later in 2026. Investors remain focused on dilution risks and upcoming updates from management. CEO Paul Bolno will present at the J.P. Morgan Healthcare Conference on January 13.
9 January 2026
·
Applied Materials stock jumps toward $300 as TSMC sales beat and analysts lift AMAT targets

Applied Materials stock jumps toward $300 as TSMC sales beat and analysts lift AMAT targets

Applied Materials shares jumped about 6% Friday, briefly topping $300, after TSMC reported fourth-quarter revenue above forecasts. Other chip-equipment stocks also rose, with Lam Research up 8% and KLA up 5%. Investors are watching TSMC’s Jan. 15 outlook and Applied’s next earnings report for signs on 2026 spending.
9 January 2026
·····
1 … 573 574 575 576 577 … 1,359

Stock Market Today

  • TCS Stock Gains on AI Contract Optimism, Closes at INR 2,383.80 on NSE
    March 23, 2026, 8:53 AM EDT. Tata Consultancy Services (TCS.NS) stock closed at INR 2,383.80 on March 23, 2026, up 1.18% with volumes exceeding the average. Investors are focusing on AI-related contracts and guidance ahead of the April earnings call. The stock trades below its 50- and 200-day moving averages amid technology sector weakness but offers a solid trailing PE of 18.14 and strong fundamentals, including a return on equity of 46.26%. TCS's AI platforms, including TwinX and ignio, are driving growth expectations in banking, retail, and life sciences. Technical indicators show the stock as oversold, while AI-driven revenue growth remains a key catalyst. Meyka AI rates TCS a B+ with a 12-month price target of INR 2,800, highlighting a potential 17.46% upside.
Go toTop